Eryngium caeruleum: an update on ethnobotany, phytochemistry and biomedical applications.
Bioactive molecules
Eryngium caeruleum
Ethnobotany
Pharmacological activities
Journal
Chinese medicine
ISSN: 1749-8546
Titre abrégé: Chin Med
Pays: England
ID NLM: 101265109
Informations de publication
Date de publication:
29 Sep 2022
29 Sep 2022
Historique:
received:
23
05
2022
accepted:
16
09
2022
entrez:
29
9
2022
pubmed:
30
9
2022
medline:
30
9
2022
Statut:
epublish
Résumé
A biennial or perennial plant of the Apiaceae family, Eryngium caeruleum M. Bieb. is traditionally used in medicine as an antitoxic, diuretic, digestive, anti-inflammatory and analgesic drug. This plant is widely distributed in temperate regions around the world. Young leaves of the plant are used in cooking as aromatic cooked vegetables in various local products in Iran. The current review aimed to highlight complete and updated information about the Eryngium caeruleum species, regarding botanical, ethnopharmacological, phytochemical data, pharmacological mechanisms as well as some nutritional properties. All this scientific evidence supports the use of this species in complementary medicine, thus opening new therapeutic perspectives for the treatment of some diseases. The information provided in this updated review is collected from several scientific databases such as PubMed/Medline, ScienceDirect, Mendeley, Scopus, Web of Science and Google Scholar. Ethnopharmacology books and various professional websites were also researched. The phytochemical composition of the aerial parts and roots of E. caeruleum is represented by the components of essential oil (EO), phenolic compounds, saponins, protein, amino acids, fiber, carbohydrates, and mineral elements. The antioxidant, antimicrobial, antidiabetic, antihypoxic, and anti-inflammatory properties of E. caeruleum have been confirmed by pharmacological experiments with extracts using in vitro and in vivo methods. The syrup E. caeruleum relieved dysmenorrhea as effectively as Ibuprofen in the blinded, randomized, placebo-controlled clinical study. Current evidence from experimental pharmacological studies has shown that the different bioactive compounds present in the species E. caeruleum have multiple beneficial effects on human health, being potentially active in the treatment of many diseases. Thus, the traditional uses of this species are supported based on evidence. In future, translational and human clinical studies are necessary to establish effective therapeutic doses in humans.
Sections du résumé
BACKGROUND
BACKGROUND
A biennial or perennial plant of the Apiaceae family, Eryngium caeruleum M. Bieb. is traditionally used in medicine as an antitoxic, diuretic, digestive, anti-inflammatory and analgesic drug. This plant is widely distributed in temperate regions around the world. Young leaves of the plant are used in cooking as aromatic cooked vegetables in various local products in Iran.
PURPOSE
OBJECTIVE
The current review aimed to highlight complete and updated information about the Eryngium caeruleum species, regarding botanical, ethnopharmacological, phytochemical data, pharmacological mechanisms as well as some nutritional properties. All this scientific evidence supports the use of this species in complementary medicine, thus opening new therapeutic perspectives for the treatment of some diseases.
METHODS
METHODS
The information provided in this updated review is collected from several scientific databases such as PubMed/Medline, ScienceDirect, Mendeley, Scopus, Web of Science and Google Scholar. Ethnopharmacology books and various professional websites were also researched.
RESULTS
RESULTS
The phytochemical composition of the aerial parts and roots of E. caeruleum is represented by the components of essential oil (EO), phenolic compounds, saponins, protein, amino acids, fiber, carbohydrates, and mineral elements. The antioxidant, antimicrobial, antidiabetic, antihypoxic, and anti-inflammatory properties of E. caeruleum have been confirmed by pharmacological experiments with extracts using in vitro and in vivo methods. The syrup E. caeruleum relieved dysmenorrhea as effectively as Ibuprofen in the blinded, randomized, placebo-controlled clinical study.
CONCLUSION
CONCLUSIONS
Current evidence from experimental pharmacological studies has shown that the different bioactive compounds present in the species E. caeruleum have multiple beneficial effects on human health, being potentially active in the treatment of many diseases. Thus, the traditional uses of this species are supported based on evidence. In future, translational and human clinical studies are necessary to establish effective therapeutic doses in humans.
Identifiants
pubmed: 36175969
doi: 10.1186/s13020-022-00672-x
pii: 10.1186/s13020-022-00672-x
pmc: PMC9523986
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
114Informations de copyright
© 2022. The Author(s).
Références
Exp Ther Med. 2017 May;13(5):2375-2381
pubmed: 28565851
Mol Phylogenet Evol. 2008 Mar;46(3):1129-50
pubmed: 18178486
Exp Ther Med. 2020 Jan;19(1):717-721
pubmed: 31885709
Evid Based Complement Alternat Med. 2022 Mar 7;2022:6727609
pubmed: 35295925
Int J Mol Sci. 2020 Feb 12;21(4):
pubmed: 32059471
Int J Mol Med. 2019 Aug;44(2):375-389
pubmed: 31173155
Oxid Med Cell Longev. 2022 Jan 19;2022:2910411
pubmed: 35096265
Daru. 2017 Apr 17;25(1):10
pubmed: 28416008
Oxid Med Cell Longev. 2022 Apr 25;2022:8615242
pubmed: 35509838
Oxid Med Cell Longev. 2021 Dec 28;2021:1602437
pubmed: 34992714
Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):946-9
pubmed: 27010155
Oxid Med Cell Longev. 2022 Feb 4;2022:6025900
pubmed: 35154569
Eur Rev Med Pharmacol Sci. 2012 Jul;16 Suppl 3:81-7
pubmed: 22957421
Food Chem Toxicol. 2020 Jan;135:111038
pubmed: 31825855
Antibiotics (Basel). 2021 Jul 16;10(7):
pubmed: 34356789
Fitoterapia. 2011 Apr;82(3):302-8
pubmed: 21062639
Oxid Med Cell Longev. 2022 Feb 1;2022:3079577
pubmed: 35154564
Biomed Pharmacother. 2022 Oct;154:113555
pubmed: 36027610
Oxid Med Cell Longev. 2022 Jan 13;2022:8442734
pubmed: 35069979
Z Naturforsch C J Biosci. 2022 Sep 07;:
pubmed: 36069757
Cancer Cell Int. 2022 Jul 28;22(1):239
pubmed: 35902860
Front Pharmacol. 2020 Oct 22;11:571459
pubmed: 33192514
Oncol Lett. 2019 May;17(5):4094-4101
pubmed: 30944602
Chin Med. 2021 Dec 24;16(1):143
pubmed: 34952619
J Clin Med. 2019 Nov 01;8(11):
pubmed: 31683787
Oxid Med Cell Longev. 2021 Aug 23;2021:6492346
pubmed: 34531939
Int J Mol Med. 2021 Nov;48(5):
pubmed: 34515324
Rom J Morphol Embryol. 2015;56(1):175-81
pubmed: 25826503
Photodiagnosis Photodyn Ther. 2021 Dec;36:102542
pubmed: 34547470
Front Pharmacol. 2021 May 11;12:600139
pubmed: 34045956
Biomedicines. 2020 May 15;8(5):
pubmed: 32429264
J Oncol. 2021 Dec 10;2021:5905357
pubmed: 34925509
Front Pharmacol. 2021 Aug 24;12:674682
pubmed: 34504422
Biomed Res Int. 2022 Feb 2;2022:1375892
pubmed: 35155670
Exp Ther Med. 2019 Feb;17(2):1113-1124
pubmed: 30679982
Front Pharmacol. 2021 Jan 14;11:578823
pubmed: 33628170
Evid Based Complement Alternat Med. 2022 Feb 24;2022:4024331
pubmed: 35251206
Phytother Res. 2021 Mar;35(3):1187-1217
pubmed: 33025667
Mol Med Rep. 2016 Dec;14(6):5501-5506
pubmed: 27840992
J Clin Med. 2021 Feb 06;10(4):
pubmed: 33562115
Oxid Med Cell Longev. 2022 Sep 5;2022:5628601
pubmed: 36105486
Daru. 2015 Dec 14;23:53
pubmed: 26667677
Plants (Basel). 2022 Jul 20;11(14):
pubmed: 35890519
Eur J Med Chem. 2022 Apr 5;233:114217
pubmed: 35276425
BMC Complement Altern Med. 2016 Nov 24;16(1):478
pubmed: 27881119
Exp Ther Med. 2018 Dec;16(6):4499-4510
pubmed: 30542398
Taiwan J Obstet Gynecol. 2019 Mar;58(2):227-233
pubmed: 30910144
Oncol Lett. 2019 May;17(5):4170-4175
pubmed: 30944612
Cancer Cell Int. 2022 Sep 8;22(1):280
pubmed: 36076273
F1000Res. 2017 Sep 5;6:1645
pubmed: 28944048
Mol Med Rep. 2019 Oct;20(4):3701-3708
pubmed: 31485647
J Food Drug Anal. 2016 Jan;24(1):179-188
pubmed: 28911402
Prog Biomater. 2022 Jul 29;:
pubmed: 35904711
Int J Mol Med. 2019 Jul;44(1):218-226
pubmed: 31115552
J Pers Med. 2021 May 31;11(6):
pubmed: 34072930
Chin Med. 2021 Dec 20;16(1):138
pubmed: 34930402
Front Pharmacol. 2021 Jan 18;11:592654
pubmed: 33536909
Iran J Med Sci. 2016 May;41(3 Suppl):S18
pubmed: 27840484
Eur Rev Med Pharmacol Sci. 2015 Sep;19(17):3282-5
pubmed: 26400535
Biomed Res Int. 2022 Mar 4;2022:9349897
pubmed: 35281611
Front Pharmacol. 2021 Jun 17;12:665031
pubmed: 34220504
J Ethnopharmacol. 2020 Jan 10;246:112230
pubmed: 31526860
Molecules. 2019 May 14;24(10):
pubmed: 31091784
Neurochem Res. 2021 Sep;46(9):2205-2225
pubmed: 34120291
J Clin Med. 2020 Jul 27;9(8):
pubmed: 32726998